Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Convertible Series F Preferred Stock
Convertible Series D Preferred Stock
Redeemable Convertible Series B Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2017 $ 1,777,781 $ 169,447 $ 822,201 $ 33,623 $ 10,427,742 $ (14,030,871) $ (3,569,506)
Balance (in shares) at Dec. 31, 2017 2,000 200 2,834 33,622,829      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation expense       $ 2,500 227,109   229,609
Stock based compensation expense (in shares)       2,500,000      
Issuance of common stock net of issuance costs of $16,900       $ 32,500 (32,500)    
Issuance of common stock net of issuance costs of $16,900 (in shares)       32,500,000      
Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share     $ (822,201) $ 28,385 800,530   828,915
Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share (in shares)     (2,834) 28,385,000      
Conversion of Series D Preferred Stock to common stock at $0.10 per share   $ (169,447)   $ 2,000 167,447   169,447
Conversion of Series D Preferred Stock to common stock at $0.10 per share (in shares)   (200)   2,000,000      
Conversion of Series F Preferred Stock to common stock at $0.10 per share $ (1,777,781)     $ 20,000 1,757,781   1,777,781
Conversion of Series F Preferred Stock to common stock at $0.10 per share (in shares) (2,000)     20,000,000      
Conversion of secured convertible promissory note - related party and accrued interest       $ 9,000 1,691,878   1,700,878
Conversion of secured convertible promissory note - related party and accrued interest (in shares)       9,000,000      
Series B warrant exercises       $ 4,406 1,318,284   1,322,690
Series B warrant exercises (in shares)       4,406,250      
Net loss           (8,213,793) (8,213,793)
Balance at Mar. 31, 2018       $ 132,414 16,358,271 (22,244,664) (5,753,979)
Balance (in shares) at Mar. 31, 2018       132,414,079      
Balance at Dec. 31, 2017 $ 1,777,781 $ 169,447 $ 822,201 $ 33,623 10,427,742 (14,030,871) (3,569,506)
Balance (in shares) at Dec. 31, 2017 2,000 200 2,834 33,622,829      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss             (12,972,142)
Balance at Sep. 30, 2018       $ 133,445 16,714,448 (27,003,013) (10,155,120)
Balance (in shares) at Sep. 30, 2018       133,445,080      
Balance at Mar. 31, 2018       $ 132,414 16,358,271 (22,244,664) (5,753,979)
Balance (in shares) at Mar. 31, 2018       132,414,079      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation expense         100,603   100,603
Common stock issuance costs paid of $7,778         (7,778)   (7,778)
Series B warrant exercises       $ 288 77,587   77,875
Series B warrant exercises (in shares)       287,500      
Net loss           (2,662,000) (2,662,000)
Balance at Jun. 30, 2018       $ 132,702 16,528,683 (24,906,664) (8,245,279)
Balance (in shares) at Jun. 30, 2018       132,701,579      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation expense       $ 643 153,865   154,508
Stock based compensation expense (in shares)       643,501      
Series B warrant exercises       $ 100 31,900   32,000
Series B warrant exercises (in shares)       100,000      
Net loss           (2,096,349) (2,096,349)
Balance at Sep. 30, 2018       $ 133,445 16,714,448 (27,003,013) (10,155,120)
Balance (in shares) at Sep. 30, 2018       133,445,080      
Balance at Dec. 31, 2018       $ 133,908 17,528,947 (33,225,107) (15,562,252)
Balance (in shares) at Dec. 31, 2018       133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation expense         171,493   171,493
Warrants issued in connection with convertible multi-draw credit agreement, related party         716,110   716,110
Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party         1,584,850   1,584,850
Net loss           (14,774,392) (14,774,392)
Balance at Mar. 31, 2019       $ 133,908 20,001,400 (47,999,499) (27,864,191)
Balance (in shares) at Mar. 31, 2019       133,907,747      
Balance at Dec. 31, 2018       $ 133,908 17,528,947 (33,225,107) (15,562,252)
Balance (in shares) at Dec. 31, 2018       133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss             (3,800,227)
Balance at Sep. 30, 2019       $ 134,095 20,488,778 (37,025,334) (16,402,461)
Balance (in shares) at Sep. 30, 2019       134,095,247      
Balance at Mar. 31, 2019       $ 133,908 20,001,400 (47,999,499) (27,864,191)
Balance (in shares) at Mar. 31, 2019       133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation expense         173,084   173,084
Series B warrant exercises       $ 187 144,188   144,375
Series B warrant exercises (in shares)       187,500      
Net loss           15,905,290 15,905,290
Balance at Jun. 30, 2019       $ 134,095 20,318,672 (32,094,209) (11,641,442)
Balance (in shares) at Jun. 30, 2019       134,095,247      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation expense         170,106   170,106
Net loss           (4,931,125) (4,931,125)
Balance at Sep. 30, 2019       $ 134,095 $ 20,488,778 $ (37,025,334) $ (16,402,461)
Balance (in shares) at Sep. 30, 2019       134,095,247